-
WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to placebo, improving the ability of blood to transition through the lungs to the heart
-
These data support proof-of-concept to inform Phase 3 development for WINREVAIR in this population
November 18, 2025--RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ (sotatercept-csrk) in adults for the treatment of combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary vascular resistance (PVR) from baseline at 24 weeks compared to placebo. Based on a preliminary assessment, the safety profile observed in the CADENCE study was generally consistent with the known safety profile for WINREVAIR.
“In this study, WINREVAIR improved pulmonary vascular resistance, an important hemodynamic measurement related to cardiac and pulmonary blood vessel function that has the potential to translate into improved outcomes for patients with combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction,” said Dr. Mahesh Patel, vice president, global clinical development, Merck Research Laboratories. “The CADENCE trial was designed as a proof-of-concept study to evaluate the pharmacological activity of WINREVAIR in a new patient population, with the goal of informing further Phase 3 development.”
The company is planning to present these results at a future scientific congress and intends to proceed with Phase 3 development.
WINREVAIR is U.S. Food and Drug Administration (FDA) approved as an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO* Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. WINREVAIR is currently approved in more than 50 countries.
* World Health Organization
About the CADENCE Study
CADENCE is a randomized, double-blind randomized, placebo-controlled Phase 2 proof-of-concept study (NCT04945460) evaluating the efficacy and safety of WINREVAIR versus placebo in adults with CpcPH due to HFpEF. Adult patients in the trial had a diagnosis of CpcPH due to HFpEF with New York Heart Association (NYHA) FC II or III. CADENCE was designed as proof-of-concept study with biomarkers, invasive hemodynamics, non-invasive imaging and exercise capacity. The primary endpoint is change from baseline in PVR. The study further assessed exercise capacity, echocardiographic endpoints, biomarker endpoints and clinical endpoints.
The study enrolled 164 participants, who were randomized in a 1:1:1 ratio to one of the three treatment groups (placebo, 0.3mg/kg WINREVAIR and 0.7mg/kg WINREVAIR) during the placebo-controlled treatment period.
About Combined Postcapillary and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as Group 2 pulmonary hypertension. CpcPH is associated with poorer outcomes compared to other types of Group 2 PH. It is harder to treat because it involves both advanced left-sided heart disease and progressive remodeling of the pulmonary vasculature. There are no treatments specifically approved for CpcPH today. CpcPH due to HFpEF is believed to be a rare, though potentially underdiagnosed condition.
About WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.